# US 2018/0023072 A1 · Beta-lactamases with improved properties for therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0023072 A1
- Document ID: US20180023072A1
- Status: Published application
- Kind: A1
- Application number: 15/674,177
- Filed: 2017-08-10
- Published: 2018-01-25
- Earliest claimed: 2014-04-17
- Assignees: Synthetic Biologics, Inc.
- Applicants: Synthetic Biologics, Inc.
- Inventors: Michael Kaleko; Sheila Connelly
- Web page: https://patentgrep.com/patent/US20180023072A1

## CPC

- C12N 9/86: acting on amide bonds in cyclic amides, e.g. penicillinase {(3.5.2)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/546: containing further heterocyclic rings, e.g. cephalothin
- A61K 38/50: acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 39/02: Antidotes
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12Y 305/02006: Beta-lactamase (3.5.2.6)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).

## Claims

### Claim at position 1

1-73. (canceled)

### Claim 74

A beta-lactamase comprising an amino acid sequence having at least 95% sequence identity with SEQ ID NO: 1 and having a polar and neutral hydrophilic residue other than alanine (A) at position 238 according to Ambler classification.

### Claim 75 (depends on 74)

The beta-lactamase of claim 74, further comprising a polar and positively charged hydrophilic residue other than glycine (G) at position 156 according to Ambler classification.

### Claim 76 (depends on 74)

The beta-lactamase of claim 74, further comprising a polar and neutral hydrophilic residue other than aspartate (D) at position 276 according to Ambler classification.

### Claim 77 (depends on 76)

The beta-lactamase of claim 76, further comprising an aromatic hydrophobic residue other than phenylalanine (F) at position 33 according to Ambler classification.

### Claim 78 (depends on 74)

The beta-lactamase of claim 74, wherein the polar and neutral hydrophilic residue is selected from asparagine (N), glutamine (Q), serine (S), threonine (T), proline (P), and cysteine (C).

### Claim 79 (depends on 75)

The beta-lactamase of claim 75, wherein the polar and positively charged hydrophilic residue is selected from arginine (R), and lysine (K).

### Claim 80 (depends on 76)

The beta-lactamase of claim 76, wherein the polar and neutral hydrophilic residue is selected from asparagine (N), glutamine (Q), serine (S), threonine (T), proline (P), and cysteine (C).

### Claim 81 (depends on 77)

The beta-lactamase of claim 77, wherein the aromatic hydrophobic residue is selected from tryptophan (W), and tyrosine (Y).

### Claim 82 (depends on 74)

The beta-lactamase of claim 74, wherein the beta-lactamase hydrolyzes one or more of penicillins and cephalosporins.

### Claim 83 (depends on 82)

The beta-lactamase of claim 82, wherein the penicillin is ampicillin.

### Claim 84 (depends on 82)

The beta-lactamase of claim 82, wherein the cephalosporin is selected from ceftriaxone, cefotaxime, cefozolin, cefoperazone, cefepime, cefuroxime, and ceftazidime.

### Claim 85 (depends on 74)

The beta-lactamase of claim 74, wherein the beta-lactamase has improved catalytic efficiency against cephalosporins as compared to SEQ ID NO: 1.

### Claim 86 (depends on 85)

The beta-lactamase of claim 85, wherein the beta-lactamase has about a 10 fold to about a 1000 fold improved catalytic efficiency against a cephalosporin as compared to SEQ ID NO: 1.

### Claim 87 (depends on 86)

The beta-lactamase of claim 86, wherein the cephalosporin is selected from ceftriaxone, cefotaxime, cefozolin, cefoperazone, cefepime, cefuroxime, and ceftazidime.

### Claim 88 (depends on 74)

The beta-lactamase of claim 74, wherein the beta-lactamase is active in the GI tract.

### Claim 89 (depends on 88)

The beta-lactamase of claim 88, wherein the beta-lactamase is stable in the small intestine, optionally selected from one or more of the duodenum, jejunum, and ileum.

### Claim 90 (depends on 74)

A polynucleotide comprising a polynucleotide sequence encoding the beta-lactamase of claim 74.

### Claim 91 (depends on 90)

A host cell comprising the polynucleotide of claim 90.

### Claim 92 (depends on 74)

A pharmaceutical composition, comprising the beta-lactamase of claim 74 and a pharmaceutically acceptable carrier or excipient.

### Claim 93 (depends on 92)

The pharmaceutical composition of claim 92, wherein the composition is formulated for oral administration, optionally selected from a tablet, multi-particulate sprinkle, and a multi-particulate capsule.

### Claim 94

A method for preventing an antibiotic-induced adverse effect in the gastrointestinal (GI) tract, comprising administering an effective amount of a beta-lactamase to a patient in need thereof, wherein the beta-lactamase comprises an amino acid sequence having at least 95% sequence identity with SEQ ID NO: 1 and having a polar and neutral hydrophilic residue other than alanine (A) at position 238 according to Ambler classification.

### Claim 95 (depends on 94)

The method of claim 94, further comprising a polar and positively charged hydrophilic residue other than glycine (G) at position 156 according to Ambler classification.

### Claim 96 (depends on 94)

The method of claim 94, further comprising a polar and neutral hydrophilic residue other than aspartate (D) at position 276 according to Ambler classification.

### Claim 97 (depends on 96)

The method of claim 96, further comprising an aromatic hydrophobic residue other than phenylalanine (F) at position 33 according to Ambler classification.

### Claim 98 (depends on 94)

The method of claim 94, wherein the polar and neutral hydrophilic residue is selected from asparagine (N), glutamine (Q), serine (S), threonine (T), proline (P), and cysteine (C).

### Claim 99 (depends on 95)

The method of claim 95, wherein the polar and positively charged hydrophilic residue is selected from arginine (R), and lysine (K).

### Claim 100 (depends on 96)

The method of claim 96, wherein the polar and neutral hydrophilic residue is selected from asparagine (N), glutamine (Q), serine (S), threonine (T), proline (P), and cysteine (C).

### Claim 101 (depends on 97)

The method of claim 97, wherein the aromatic hydrophobic residue is selected from tryptophan (W), and tyrosine (Y).

### Claim 102 (depends on 94)

The method of claim 94, wherein the subject is being administered or will be administered an antibiotic.

### Claim 103 (depends on 94)

The method of claim 94, wherein the antibiotic-induced adverse effect is C. difficile infection (CDI) and/or a C. difficile-associated disease.

### Claim 104 (depends on 103)

The method of claim 103, wherein the C. difficile-associated disease is antibiotic-associated diarrhea (AAD).
